Category: InVivo Therapeutics Corp.
InVivo Therapeutics gets a green light to reopen enrollment in a clinical study of its neuro-spinal scaffold for treating acute spinal cord injuries.
The FDA approves an expedited enrollment plan for a 5-patient pivotal study testing InVivo Therapeutics' neuro-spinal scaffold devices in the treatment of severe spinal cord injuries.
Here's a look at some of the top Wall Street stories for medical device companies this week: InVivo shares soar on spinal cord study update; Actavis trumps Valeant with $66B offer for Allergan; Medtronic's Q2 results meet The Street; Venture capital investment in medtech grows in Q3
InVivo Therapeutics shares soar after Arizona doctors confirm they have treated the first patient in a study for the company's experimental bio-scaffolding device for acute spinal-cord injuries.
Here's a look at some of the top Wall Street stories for medical device companies this week: Second suitor ceded early to Zimmer in chase for Biomet; Kimberly-Clark readies Halyard Health medical device spinout; InVivo's stock drops as ex-CEO dumps shares; Mevion Medical files for $69M IPO; ReWalk Robotics prices IPO at $36M, below range
InVivo Therapeutics ex-CEO Frank Reynolds has been liquidating his position in the company, putting even more weight on NVIV's already-pressured shares.
As if InVivo Therapeutics (OTC:NVIV) wasn't having a tough enough time already, the company's stock is under even more pressure as former CEO Frank Reynolds has been liquidating his position over the last few weeks.
Here's a look at some of the top legal news stories for medical device companies this week: Mirowski wants another bite at Supreme Court apple in Medtronic lawsuit; Shareholders sue InVivo Therapeutics, ex-CEO Reynolds over delayed FDA trial; Retractable Technologies urges appeals court to leave infringement win over BD alone; Boston Scientific can't sever Pinnacle pelvic mesh cases; Allergan can't delay shareholder vote on hostile Valeant bid